Protective effects of certoparin sodium, a low molecular weight heparin derivative, in experimental atherosclerosis

Clinica Chimica Acta

Volumn 339, Issue 1-2, 2004, Pages 105-115

  Deepa, Perinkulam Ravi ^a   Varalakshmi, Palaninathan ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Atherosclerosis; Glycosaminoglycans; Heparin; Hypercholesterolemia; Low molecular weight heparin

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMINOTRANSFERASE; CERTOPARIN SODIUM; CHOLESTEROL; CHOLIC ACID; CREATININE; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; THIOURACIL; TRIACYLGLYCEROL; TROPARIN; UNCLASSIFIED DRUG; UREA; URIC ACID;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROGENIC DIET; ATHEROSCLEROSIS; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIET SUPPLEMENTATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; FATTY LIVER; FEEDING; FOOD COMPOSITION; HEART DISEASE; HEMOCONCENTRATION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTROPHIC CARDIOMYOPATHY; KIDNEY DISEASE; LIVER DISEASE; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTECTION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

RATTUS NORVEGICUS;

EID: 0346366548     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.09.021     Document Type: Article

References (48)

1. Choay J., Petitou M. The chemistry of heparin: a way to understand its mode of action. Med. J. Aust. 144:1986;7-10.
2. Rogers K.A., Karnovsky M.J. A rapid method for the detection of early stages of atherosclerotic lesion formation. Am. J. Pathol. 133:1988;451-455.
3. Peric-Golia L., Peric-Golia M. Aortic and renal lesions in hypercholesterolemic adult, male, virgin Sprague-Dawley rats. Atherosclerosis. 46:1983;57-65.
4. Reinhold J.G. Total protein albumin and globulin. Seligson D. Standard Methods of Clinical Chemistry. vol. 1:1953;88 Academic Press, New York.
5. Natelson S. Techniques of Clinical Chemistry. vol. 3:1971;684-688 Charles C. Thomas, Springfield IL, USA.
6. Caraway W.T. Uric acid. Seligson D. Standard Methods of Clinical Chemistry. vol. 4:1965;239-247 Academic Press, New York.
7. Owens J.K., Iggo B., Scandretta F.J., Stewart C.P. Determination of creatinine in plasma or serum and in urine: a critical examination. Biochem. J. 58:1954;426-437.
8. Okinaka S., Sugita H., Momoi H., Toyokura Y., Watanabe T., Ebashi F.et al. Cysteine-stimulated serum creatine kinase in health and disease. J. Lab. Clin. Med. 64:1964;299-305
9. King J. Practical clinical enzymology. Van D. The Dehydrogenases or Oxidoreductases-Lactate Dehydrogenase. 1965;83-93
10. King J. Practical clinical enzymology. Van D. The Transferases Alanine and Aspartate Transaminases. 1965;121-138
11. King J. Practical clinical enzymology. Van D. The Hydrolases-acid and Alkaline Phosphatase. 1965;191-208 Nostrand Company Limited, London.
12. Parekh A.C., Jung D.H. Cholesterol determination with ferric chloride-uranium acetate and sulfuric acid-ferrous sulphate reagents. Anal. Chem. 42:1970;1423-1427.
13. Rice E.W. Triglycerides ("neutral fats") in serum. MacDonald R.P. Standard Methods of Clinical Chemistry. vol. 6:1970;215-222 Academic Press, New York.
14. Wilson D.E., Spiger M.J. A dual precipitation method for quantitative lipoprotein measurement without ultracentrifugation. J. Lab. Clin. Med. 82:1973;473-483.
15. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340:1999;115-126.
16. Joris I., Zand T., Nunnari J.J., Krolikowski F.J., Majno G. Studies on the pathogenesis of atherosclerosis: I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am. J. Pathol. 113:1983;341-358.
17. Ross R. The pathogenesis of atherosclerosis: an update. N. Engl. J. Med. 314:1986;488-500.
18. Silkworth J.B., McLean B., Stehbens W.E. The effect of hypercholesterolemia on aortic endothelium studied en face. Atherosclerosis. 22:1975;335-348.
19. Florentin R.A., Nam S.C., Lee K.T., Lee K.J., Thomas W.A. Increased mitotic activity in aortas of swine after three days of cholesterol feeding. Arch. Pathol. 88:1969;463-469.
20. Stemerman M.B. Effects of moderate hypercholesterolemia on rabbit endothelium. Arteriosclerosis. 1:1981;25-32.
21. Virchow R. A more precise account of fatty metamorphosis. Chance F. Cellular Pathology. 2nd ed. 1960;342-366 Birmingham, AL, Gryphon.
22. Grond J., Weening J.J., Elema J.D. Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of Adriamycin and aminonucleoside. Lab. Invest. 51:1984;277-285. [translator].
23. Thomas W.A., Kim D.N. Atherosclerosis as a hyperplastic and/or neoplastic process. Lab. Invest. 48:1983;245-255.
24. Engelberg H. Heparin and the atherosclerotic process. Pharmacol. Rev. 36(2):1984;91-110.
25. Hansson G.K., Bondjers G., Nilsson L.A. Plasma protein accumulation in injured endothelial cells. Immunofluorescence localization of IgG and fibrinogen in the rabbit aortic endothelium. Exp. Mol. Pathol. 30:1979;13-26.
26. Engelberg H. Update on the relationship of heparin to atherosclerosis and its thrombotic complications. Semin. Thromb. Hemost. 14:1988;88-105. [Suppl.].
27. Engelberg H. Actions of heparin in the atherosclerotic process. Pharmacol. Rev. 48(2):1996;327-352.
28. Nelson R.M., Cecconi O., Roberts W.G., Aruffo A., Linhardt R.J., Bevilacqua M.P. Heparin oligosaccharides bind L- and P-Selectin and inhibit acute inflammation. Blood. 82(11):1993;3253-3258.
29. Ward H.J. Uric acid as an independent risk factor in the treatment of hypertension. Lancet. 352:1998;670-671.
30. Ohno I., Hosoya T., Gomi H., Ichida K., Okabe H., Hikita M. Serum uric acid and renal prognosis in patients with Ig A nephropathy. Nephron. 87:2001;333-339.
31. Hooper D.C., Spitsin S., Kean R.B., Champion J.M., Dickson G.M., Chaudhry I.et al. Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 95:1998;657-680.
32. Suarna C., Dean R.T., May J., Stocker R. Human atherosclerosis plaque contains both oxidised lipids and relatively large amounts alpha-tocopherol and ascorbate. Arterioscler. Thromb. Vasc. Biol. 15:1995;1616-1624.
33. Kahn A., Brachet E., Conard V. Correlation between albumin permeability and concentrations of adenosine cyclic monophosphate in the incubated rat mesentary. C. R. Seances Soc. Biol. Ses. Fil. 170:1976;227-230.
34. Stefoni S., Cianciolo G., Donati G., Dormi A., Silvestri M.G., Coli L.et al. Low TGF-β1 serum concentrations are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int. 61:2002;324-335.
35. Naik S.R., Sheth U.K. Studies on two new derivatives of N-aralykyl-O-etoxybenzomide. Part II:biochemical studies on their antiinflammatory activity. Indian J. Exp. Biol. 16:1978;1175-1179.
36. Gallo R.L., Dorschner R.A., Takashima S., Klagsbru M., Eriksson E., Bernfield M. Endothelial cell surface alkaline phosphatase activity is induced by IL-6 released during wound repair. J. Invest. Dermatol. 109(4):1997;597-603.
37. Scalia R., Appel J.Z. III, Lefer A.M. Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit: role of P-selectin ICAM-1 and VCAM-1. Arterioscler. Thromb. Vasc. Biol. 18:1998;1093-1100.
38. Stokes K.Y., Clanton E.C., Russell J.M., Ross C.R., Granger D.N. NAD(P)H oxidase-derived superoxide mediates hypercholesterolemia-induced leukocyte-endothelial cell adhesion. Circ. Res. 88:2001;499-505.
39. Stokes K.Y., Cooper D., Tailor A., Granger D.N. Hypercholesterolemia promotes inflammation and microvascular dysfunction: role of nitric oxide and superoxide. Free Radic. Biol. Med. 33(8):2002;1026-1036.
40. Engelberg H. Heparin and atherosclerosis. A review of old and recent findings. Am. Heart J. 99(3):1980;359-372.
41. Persson E., Nordenstrom J., Nilsson-Ehle P., Hagenfeldt L. Lipolytic and anticoagulant activities of a low molecular weight fragment of heparin. Eur. J. Clin. Invest. 15:1985;215-220.
42. Astrup P. Effects of hypoxia and of carbon monoxide exposures on experimental atherosclerosis. Ann. Intern. Med. 71:1969;426-427.
43. Steinbach J.H., Blackshear P.L., Varco R.L., Buchwald H. High blood cholesterol reduces in vitro blood oxygen delivery. J. Surg. Res. 16:1974;134-139.
44. Engelberg H. Serum lipemia: an overlooked cause of tissue hypoxia. Cardiology. 70(5):1983;273-279.
45. Deepa P.R., Varalakshmi P. Favourable influence of low molecular weight heparin in mitigating the peroxidative membrane damage induced by a cytotoxic agent and an atherogenic diet. Human Exp. Toxicol. 22:2003;229-235.
46. Deepa P.R., Varalakshmi P. Salubrious effect of low molecular weight heparin on atherogenic diet-induced cardiac, hepatic and renal lipid peroxidation and collapse of antioxidant defences. Mol. Cell. Biochem. 254:2003;111-116.
47. Campos S.B., Ori M., Dorea E.L., Seguro A.C. Protective effect of L-arginine on hypercholesterolemia-enhanced renal ischemic injury. Atherosclerosis. 143:1999;327-334.
48. Akimoto H., Ito H., Tanaka M.et al. Heparin and heparan sulfate block angiotensin II-induced hypertrophy in cultured neonatal rat cardiomyocytes. A possible role of intrinsic heparin-like molecules in regulation of cardiomyocyte hypertrophy. Circulation. 93(4):1996;810-816.